Homepage Top Section1

AZD1222 was co-invented by Oxford University and its spin-out company Vaccitech. The recombinant adenovirus vaccine, which was licensed by AstraZeneca in May 2020, was tolerated by the participants

The late-stage study of the Covid-19 inactivated vaccine candidate marks the first phase 3 clinical trial for any vaccine candidate being developed in the world against the novel

Nintedanib already secured approval from the US Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) as the first treatment for

The first group of volunteers who were administered the coronavirus vaccine candidate will be discharged this week, reported Sputnik, citing the university’s Institute for Translational Medicine and Biotechnology

More than 20 biopharmaceutical companies have collaborated to establish the AMR Action Fund, which will help focus on medicines that address most resistant bacteria and life-threatening infections. The

The Series B round of Goldfinch Bio was led by Eventide Asset Management. It also included new investors – Wellington Management Company, Ally Bridge Group, Casdin Capital, funds

Theravance is considering that the TD-0903 can block the cytokine storm linked with ALI and prevent progression to acute respiratory distress syndrome (ARDS). According to the company, the

The French vaccines company, which is part of Sanofi, signed a collaboration and license agreement deal worth up to $805m with Translate Bio in 2018 for developing mRNA

The phase III IMpassion031 study assessing Tecentriq plus chemotherapy (Abraxane, albumin-bound paclitaxel, nab-paclitaxel, followed by doxorubicin and cyclophosphamide) comparison to placebo plus chemotherapy reached its primary endpoint by